Evaluation of Benztropine for Cocaine Craving - 2
Sponsor
National Institute on Drug Abuse (NIDA) (NIH)
Overall Status
Completed
CT.gov ID
NCT00000333
Collaborator
Washington D.C. Veterans Affairs Medical Center (U.S. Fed)
0
1
23
0
Study Details
Study Description
Brief Summary
The purpose of this study is to compare the efficacy of benztropine (or DA reuptake inhibitor) with atropine and placebo in affecting stimulated craving to cocaine cues.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 2 |
Study Design
Study Type:
Interventional
Primary Purpose:
Treatment
Official Title:
Evaluation of Efficacy of Benztropine for Cocaine Craving
Actual Study Start Date
:
May 1, 2001
Actual Primary Completion Date
:
Jan 1, 2003
Actual Study Completion Date
:
Apr 1, 2003
Outcome Measures
Primary Outcome Measures
- Stimulated and non-stimulated craving []
Eligibility Criteria
Criteria
Ages Eligible for Study:
22 Years
to 48 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Please contact site for information.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Washington DC VA | Washington | District of Columbia | United States | 20422 |
Sponsors and Collaborators
- National Institute on Drug Abuse (NIDA)
- Washington D.C. Veterans Affairs Medical Center
Investigators
- Principal Investigator: Steven Deutsch, M.D., Washington D.C. Veterans Affairs Medical Center
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
,
,
ClinicalTrials.gov Identifier:
NCT00000333
Other Study ID Numbers:
- NIDA-3-0009-2
- Y01-3-0009-2
First Posted:
Sep 21, 1999
Last Update Posted:
Feb 24, 2017
Last Verified:
Dec 1, 2002
Studies a U.S. FDA-regulated Drug Product:
Yes
Additional relevant MeSH terms: